Home/Pipeline/Zeta-BC-007

Zeta-BC-007

Breast Cancer

PreclinicalActive

Key Facts

Indication

Breast Cancer

Phase

Preclinical

Status

Active

Company

Zetagen Therapeutics

About Zetagen Therapeutics

Zetagen Therapeutics is a clinical-stage biotech focused on transforming the treatment of bone metastases and primary cancers through its proprietary Zeta Platform. The company's lead programs, ZetaMet and ZetaMAST, are in Phase 2a development for breast cancer bone metastases, with promising data showing complete responses and significant pain reduction. Backed by FDA Breakthrough Designations and a recent oversubscribed $12.9M Series B1 financing, Zetagen is advancing a novel treatment paradigm that combines anti-cancer, analgesic, and bone-regenerative effects in a single localized therapy.

View full company profile

Therapeutic Areas

Oncology Musculoskeletal

Other Breast Cancer Drugs

Drug	Company	Phase	Status
Antifibrotic Therapy Program	MeCo Diagnostics	Pre-clinical	Active
inPROBE for HER2	SDS Optic	Clinical Investigation	Completed (March 2023)
ACT‑BC1	Anthrocell	Preclinical	Active
APA-1000 Breast Thermotherapy System	Medifocus	Phase III	Pivotal Trial Approved (IDE/ITA)
Early‑Detection Breast Cancer Screening	Karkinos Healthcare	Market	Active
Unnamed Breast Cancer Program	Click Therapeutics	Pilot/Phase 2	Active
Lerociclib (Lerocliclib)	Chemogenics BioPharma	Phase 3	Completed Phase 3, awaiting FDA approval
AT-017	Asieris Pharmaceuticals	Not Specified	Active
CDK2 inhibitor	Acellera	Pre-clinical	Hit Identification
NP-G2-044	Novita Pharmaceuticals	Phase 2a	Active (subset)
Maveropepimut-S (MVP-S)	BioVaxys	Clinical Evaluation	Active
Cannabics® BRST-33	CNBX Pharmaceuticals	Discovery	In vitro POC